The med spa and aesthetics industry exhibited robust growth in customer demand in 2024, driving continued interest from private equity investment. A key driver behind this interest stems from the ...

The single-arm, open-label DR-OVP-002 study is currently evaluating Ovaprene in sexually active women aged 18 to 40 years who are at risk for pregnancy or desiring contraception.